¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hearing Loss, Mixed Conductive-Sensorineural"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed nerve
    È¥ÇսŰæ
  • mixed order reaction
    È¥ÇÕ¼ø¼­¹ÝÀÀ
  • mixed pineocytoma
    È¥ÇÕ¼Ö¹æ¿ï»ùÁ¾, È¥ÇÕ¼Û°úüÁ¾
  • mixed psychosis
    È¥ÇÕÁ¤½Åº´
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mixed vaccine
    È¥ÇÕ¹é½Å
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®, Çã¿ëÇ÷¾×»ó½Ç·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed gland
    È¥ÇÕ»ù
  • mixed indicator
    È¥ÇÕÁö½Ã¾à
  • mixed infection
    È¥ÇÕ°¨¿°
  • mixed beam irradiation
    È¥ÇÕºöÁ¶»ç
  • mixed joint
    È¥ÇÕ°üÀý
  • mixed nerve
    È¥ÇսŰæ
  • mixed pineocytoma
    È¥ÇÕ¼Ö¹æ¿ï»ùÁ¾
  • mixed psychosis
    È¥ÀçÁ¤½Åº´
  • mixed sequence
    º¹ÇÕ¿¬¼â
  • mixed spicule
    È¥ÇÕħ°ñ
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mixed vaccine
    È¥ÇÕ¹é½Å
  • mixed germ cell tumor
    È¥ÇÕ¹è¾Æ¼¼Æ÷Á¾¾ç
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • insensible loss
    ºÒ°¨»ó½Ç(¡­ßÃã÷).
  • insensible water loss
    ºÒ°¨¼º(ÝÕÊïàõ) ¼öºÐ»ó½Ç(â©ÝÂßÃã÷).
  • radiation loss
    ¹æ»ç¼±¼Õ½Ç
  • Frequency theory of hearing
    û°¢(ôéÊÆ)ÀÇ Áøµ¿¼ö(òÉÔÑâ¦) Çм³(ùÊàã)
  • Hearing
    û°¢(ôéÊÆ)
  • Hearing test
    û·ÂÅ×½ºÆ®
  • absolute hearing
    Àý´ëÀ½°¨
  • group hearing aid
    Áý´Üº¸Ã»±â
  • hearing =audition
    û·Â, û°¢
  • hearing =audition
    û°¢(ôéÊÆ), û·Â(ôéæ³)
  • hearing acuity
    û·Â
  • hearing aid
    º¸Ã»±â
  • hearing aid, electric
    Àü±âº¸Ã»±â
  • hearing aid, group
    Áý´Üº¸Ã»±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sensorineural hearing loss
    °¨°¢½Å°æ¼º ³­Ã»(¡­ãêÌèàõÑñôé)
  • speech hearing loss
    ¾îÀ½Ã»·Â¼Õ½Ç
  • speech hearing loss
    ¾îÀ½Ã»·Â¼Õ½Ç(¡­ôéæ³ áßã÷)
  • hearing amelioration =hearing improvement, hearin
    û·Â°³¼±
  • hearing distance =hearing range
    û·Â°Å¸®, °¡Ã»°Å¸®
  • abrasion loss
    ¸¶¸ê·®(¸¶¸ê¾ç).
  • autoimmune disease,t-supperssor function loss
    T-¾ïÁ¦¼¼Æ÷ ±â´É»ó½Ç(¡­åäð¤á¬øàѦÒößÃã÷)
  • blood loss
    ½ÇÇ÷
  • blood loss
    ½ÇÇ÷(ã÷úì).
  • blood loss
    ½ÇÇ÷(½ÇÇ÷).
  • blood loss
    ½ÇÇ÷(ã÷úì)
  • blood loss
    ½ÇÇ÷(ã÷úì)
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell loss factor
    ¼¼Æ÷¼Ò½Ç°è¼ö
  • collision loss
    Ãæµ¹¼Õ½Ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MC mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med...
MLTC mixed leukocyte-trophoblast culture; mixed lymphocyte tumor cell
LOC Loss Of Consciousness
ABCDES abnormal alignment, bones-periarticular osteoporosis, cartilage-joint space loss, deformities, margi...
ABL abetalipoproteinemia; acceptable blood loss; African Burkitt lymphoma; Albright-Butler-Lightwood [sy...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
H.L. Hearing level
HTL Hearing threshold level
NH Normal-hearing
UNHS Universal newborn hearing screening
HA hearing aid
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • weight loss
    üÁß °¨¼Ò
    ´Ü½Ä, ½ÄÀÌÁ¶Àý, º´À¸·Î ÀÎÇØ ³ªÅ¸³ª¸ç, üÁö¹æÀÇ °¨¼Ò ¶Ç´Â À½½Ä¼·Ãë ºÎÁ·À¸·Î ÀÎÇÑ ¿µ¾ç°áÇÌ ½Ã¿¡ ³ªÅ¸³­´Ù.
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • atypical or mixed organic brain syndrome
    ºñÁ¤Çü ³»Áö È¥ÇÕÇü ±âÁú¼º ³ú ÁõÈıº
  • essential mixed cryoglobulinemia
    ¿ø¹ß¼º È¥ÇÕ ÇѳÃ-±Û·Îºí¸°Áõ
    µå¹® Àü½Å¼º ÁúȯÀ¸·Î¼­ IgG-IgM º¹ÇÕü°¡ ÁÖ ¼ººÐÀÎ ÇѳÃ-±Û·Îºí¸°ÀÇ Ä§ÂøÀ¸·Î ÇǺΠÇ÷°ü¿°, Ȱ¸·¿° ¹× ÃÊÁ¡¼º ³»Áö ¹Ì¸¸¼º Áõ½Ä¼º »ç±¸Ã¼ ½Å¿°ÀÌ ³ªÅ¸³­´Ù. CÇü °£¿°°ú °°Àº °¨¿°¿¡ ¼Ó¹ßÇÏ´Â ÇѳÃ-±Û·Îºí¸°Ç÷Áõ¿¡¼­´Â ¸·Áõ½Ä¼º »ç±¸Ã¼ ½Å¿°ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù.
  • miscible : susceptible of being mixed.

    misdiagnosis

    ¿ÀÁø
  • mixed
    È¥ÇÕÇü, È¥ÇÕÇÑ, È¥¼ºÀÇ
  • mixed color
    È¥ÇÕ »ö
  • mixed cryoglobulin syndrome
    È¥ÇÕ Çѳà ±Û·ÎºÒ¸° ÁõÈıº
  • mixed deafness
    È¥ÇÕ¼º ³­Ã»
  • mixed dental arch
    È¥ÇÕ Ä¡¿­±Ã
  • mixed dentition analysis
    È¥ÇÕ Ä¡¿­±âÀÇ ¾Ç±Ã °ø°£ ºÐ¼®
    È¥ÇÕ Ä¡¿­±â ±³ÇÕÀº ¿µ±¸ Á¦1 ´ë±¸Ä¡°¡ ¸ÍÃâÇÏ´Â 6-7¼¼ºÎÅÍ Çü¼ºµÈ´Ù. ½ÃÁø ¹× ±¸°­ ¹æ»ç¼±ÇÐÀû °Ë»çÀÇ È°¿ëÀ» ÅëÇØ ¿µ±¸Ä¡ ¸ÍÃâ ¼ø¼­¸¦ »ìÆìº¸´Â °ÍÀº Á¤»ó ±³ÇÕ Çü¼ºÀÇ °¡´É¼º ÆÇ´Ü¿¡ À¯È¿ÇÑ Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù.
  • mixed echo
    È¥ÇÕ ¿¡ÄÚ, È¥ÇÕ ¸Þ¾Æ¸®
  • mixed form
    È¥ÇÕ Çü
  • mixed function oxidase
    È¥ÇÕ ±â´É ¿Á½Ãµ¥À̽º
  • mixed germ cell tumors
    È¥ÇÕ ¹è¾Æ¼¼Æ÷ Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
hair loss Hair loss may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(13 Nov 1997)
drift cyclotron loss cone instabilities (DCLC) This is an electrostatic microinstability (frequencies at harmonics of the ion cyclotron frequency) which is of major concern in small mirror devices. Mode is driven by radial gradients in the electron density, and causes loss of ions due to non-conservation of magnetic moment (see adiabatic invariant) as they interact with the mode, and are dispersed in velocity space into the loss cone. Stabilisation is accomplished by increasing the plasma size and by partially filling the loss cone with a continuous extermal warm plasma stream.
(09 Oct 1997)
eddy-current loss <radiobiology> Energy loss due to eddy currents circulating in a resistive material.
(09 Oct 1997)
tooth loss The failure to retain teeth as a result of disease or injury.
(12 Dec 1998)
functional visual loss An apparent loss of visual acuity or visual field with no substantiating physical signs; often due to a natural concern about visual loss combined with suggestibility and a fear of the worst; best treated with reassurance.
(05 Mar 2000)
loss cone In a magnetic mirror machine, particles with a large velocity parallel to the magneitc field and a small velocity perpendicular to the field will be able to escape past the magnetic mirror (see magnetic mirror). In that case the velocity distribution function (see distribution function) will be almost zero in the region of velocity space that allows particles to escape. The shape of that region (in a velocity space diagram with parallel velocity and perpendicular velocity as the axes) is a cone. When a particle undergoes a collision, its velocity gets somewhat randomised. Particles that are scattered into that cone are lost very quickly (in one mirror bounce time). Thus it is called a loss cone. Because of the loss cone, the theoretical maximum particle confinement time of a magnetic mirror machine can be only a few times the particle collision time, this is generally seen as a showstopper for mirror-based fusion research.
(09 Oct 1997)
loss of consciousness Total unresponsiveness. An important neurologic sign.
(27 Sep 1997)
loss of heterozygosity Refers to a mutation that results in the loss of allelic uniqueness, which is often defined as a greater than or equal to 40 percent increase in signal intensity of allelic signal. Loss of heterozygosity is most frequently identified in certain chromosome regions, including 5q, 17p, and 18q.
(12 Dec 1998)
malignant mixed mullerian tumour A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells.
Synonym: malignant mixed mullerian tumour.
(05 Mar 2000)
gonadal dysgenesis, mixed A syndrome of gonadal dysgenesis in which there is a testis on one side and a "streak gonad" on the other. The phenotype is generally male, but may be female since the individual is a mosaic. Various karyotypes have been identified, including 45,xo/47,xyy; 45,xo/46,xy; and 45,xo/46,xyo.
(12 Dec 1998)
mixed Formed by mixing; united; mingled; blended. See Mix, Mixed action, voices of both males and females united in the same performance.
Source: Websters Dictionary
(01 Mar 1998)
mixed agglutination Immune agglutination in which the aggregates contain cells of two different kinds but with common antigenic determinants; when used to identify isoantigens, the test cells are exposed to appropriate isoantibody, washed, and then mixed with indicator erythrocytes that combine with free sites on the test cell-attached isoantibody.
Synonym: mixed agglutination.
(05 Mar 2000)
mixed agglutination reaction Immune agglutination in which the aggregates contain cells of two different kinds but with common antigenic determinants; when used to identify isoantigens, the test cells are exposed to appropriate isoantibody, washed, and then mixed with indicator erythrocytes that combine with free sites on the test cell-attached isoantibody.
Synonym: mixed agglutination.
(05 Mar 2000)
mixed aphasia In which all aspects of speech and communication are severely impaired. at best, patients can understand or speak only a few words or phrases; they cannot read or write.
Synonym: mixed aphasia, total aphasia.
(05 Mar 2000)
mixed astigmatism Astigmatism in which one meridian is hyperopic while the one at right angle to it is myopic.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed train
    (°´Â÷¿Í È­Â÷ÀÇ) È¥¼º ¿­Â÷
  • ready-mixed
    ¹Ì¸® Á¶Á¦(Á¶ÇÕ,È¥ÇÕ)ÇÑ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á